| Category | Details |
| Definition | Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both. |
| Global Epidemiology | Affects an estimated 463 million adults worldwide in 2019, projected to rise to 643 million by 2030. |
| Type 2 diabetes accounts for approximately 90% of cases globally. |
| Increasing prevalence due to aging populations, obesity, and sedentary lifestyles. |
| Prevalence in Key Regions | United States: 38.4 million adults affected (11.3% of the population). |
| European Union: ~9% prevalence among adults, varying across countries. |
| India: Estimated 77 million adults with diabetes in 2019. |
| China: ~140 million cases, the highest global prevalence. |
| Caribbean: 13–15% prevalence among adults, representing ~3 million people. |
| Medicinal Cannabis Approvals | United States (FDA): No specific cannabinoid approved for diabetes; research focuses on inflammation and metabolic factors. |
| European Union ( EMA): Cannabinoids under investigation for glucose control and anti-inflammatory effects. |
| Canada: CBD authorized for general wellness; limited research on diabetes management. |
| Israel: Research approved for metabolic syndrome and related disorders since 2015. |
| Therapeutic Cannabinoids | CBD (Cannabidiol): Demonstrates anti-inflammatory and insulin-sensitizing effects; modulates glucose metabolism. |
| THCV (Tetrahydrocannabivarin): Enhances insulin sensitivity and reduces fasting glucose. |
| CBG (Cannabigerol): Potential anti-obesity and glucose-lowering properties in preclinical studies. |
| Mechanism of Action | CBD: Reduces oxidative stress and inflammation by modulating CB2 and PPARγ pathways; affects insulin sensitivity. |
| THCV: Acts as a CB1 antagonist to reduce appetite and improve glucose control. |
| Cannabinoids influence glucose homeostasis via interactions with the endocannabinoid system. |
| Key Clinical Studies | Jadoon et al., 2016: THCV showed reductions in fasting glucose and improved glycemic control. |
| Ratcliffe et al., 2018: THCV demonstrated significant improvements in glucose metabolism. |
| Hussain et al., 2020: Cannabinoids reduced inflammatory markers in diabetes patients. |
| Dosage Guidelines | CBD (Oral): Start with 5–10 mg/day; titrate up to 20–50 mg/day based on clinical response. |
| THCV: Initial trials suggest 10–20 mg/day effective for glucose regulation. |
| CBG: Early research supports doses of 10–15 mg/day for metabolic benefits. |
| Administration Methods | Oral Capsules: Preferred for consistent dosing and long-term management. |
| Sublingual Oils: Rapid absorption; suitable for acute symptom management. |
| Inhalation: Rarely used for diabetes; dosing variability limits its application. |
| Adverse Effects | CBD: Mild fatigue, appetite changes, diarrhea; rare liver enzyme elevation. |
| THCV: Mild gastrointestinal discomfort in early trials; no psychoactive effects. |
| CBG: Limited data; fatigue and dry mouth reported in some studies. |
| Research Gaps | Long-term safety and efficacy of cannabinoids like THCV and CBG in diabetes remain under-researched. |
| Interaction studies between cannabinoids and standard diabetes treatments needed. |
| Opportunities in the Caribbean | Prevalence: ~3 million adults affected, with limited access to comprehensive care. |
| Research: Establishing regional studies on cannabinoids for diabetes management. |
| Clinics: Cannabinoid-focused clinics could meet local needs and attract medical tourism. |
